Stockreport

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up [Seeking Alpha]

MaxCyte, Inc.  (MXCT) 
PDF Play 7min Summary MaxCyte, Inc.'s stock performance has been disappointing since its 2021 IPO, despite positive business developments and a 34% revenue growth. [Read more]